Research programme: Btk inhibitors - Celgene

Drug Profile

Research programme: Btk inhibitors - Celgene

Alternative Names: AVL -101; AVL-291; CC 90008

Latest Information Update: 26 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avila Therapeutics
  • Developer Celgene Corporation
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer

Most Recent Events

  • 11 Nov 2016 Pharmacodynamics data from in vitro and preclinical studies in Cancer presented at the 80th American College of Rheumatology and 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 11 Nov 2016 Pharmacodynamics data from a preclinical trial in Cancer presented at the 80th American College of Rheumatology (ACR-2016) and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ARHP-2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top